about
Phase 1 Trials of rVSV Ebola Vaccine in Africa and EuropePhylogenetic approach reveals that virus genotype largely determines HIV set-point viral loadAssessing predicted HIV-1 replicative capacity in a clinical settingLong-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensAdherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort StudyThe individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patientsPersistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgroundsCorrection: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing RegimensMinor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patientsHigh specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of diseaseTravel and the spread of HIV-1 genetic variants.The global spread of HIV-1 subtype B epidemic.Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmationEarly and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressorsEstimating the basic reproductive number from viral sequence data.Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland.A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.Inferring epidemic contact structure from phylogenetic trees.Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection.Generation of a recombinant Gag virus-like-particle panel for the evaluation of p24 antigen detection by diagnostic HIV tests.Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide.Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection.Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns.Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.Amplicon sequencing and improved detection of human rhinovirus in respiratory samples.Decreasing Proportion of Recent Infections among Newly Diagnosed HIV-1 Cases in Switzerland, 2008 to 2013 Based on Line-Immunoassay-Based AlgorithmsCritical analysis of rhinovirus RNA load quantification by real-time reverse transcription-PCRAviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell ResponsesIncreased incidence of sexually transmitted infections in Geneva, Switzerland.Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in SwitzerlandTracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairsA genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control.A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland.Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.Diagnosing acute HIV infection.CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV.
P50
Q24289281-FE9AA783-D8D7-42B0-87BC-52A13791CBCCQ28475652-B9006A89-E10F-4000-BA7C-1E2E9C46CB21Q28477801-42D206F5-7779-4D3F-B5A1-2379EDA96491Q28485321-C1DDB2AB-5DC4-4A0C-94C9-8C17CBDCDCBFQ28534423-0FA79E42-8351-4EAD-A6A6-CBF0FAF27DFEQ28536153-6574FEB8-2164-458C-800E-943B6190C2DCQ28544845-D450E877-41E4-4F52-814E-D4F2B2E8C7E3Q28683189-1A09562E-2525-4E12-8BFD-9E283EB10404Q28728304-ADA790F7-AB7A-4E11-9DCC-8813CFBF4938Q28744063-6C70FE5B-3B05-4D86-8CA1-852DBD44B941Q30332358-828CE67D-1DCC-4676-AC14-DCDE00128699Q30388926-0BCE1FA2-1056-4822-B38A-672A5312A7B0Q30419842-04B809F9-4605-4F15-8668-C996D1ED5669Q33308261-FEF0ABD8-C003-4BF6-BD13-7322A1F2C049Q33869222-EBF629B4-524A-4A4E-968A-47177DD28825Q34010717-D4A6A430-C1F1-405E-BD6E-82C718954D71Q34109639-F314E30E-8798-44E8-BEDC-43ED787542FBQ34127697-C238B7CE-D840-4CE6-AF4E-C1E10496E9ACQ34192802-0CD7C412-A586-46AF-AB76-DE2EA1CFB2B4Q34231138-E23EEC59-3EC2-4C22-A7C1-DE1CADFCB40FQ34400923-7BF1B404-605F-400B-AC47-2D147764BE03Q34547116-FA4A16FC-0E57-4B35-AC45-C54A0BD43B5AQ34662575-12C3C76A-02BB-47D4-B0BA-16388833086AQ34699175-1E713B0B-CDDD-46D8-B602-A8333C88240FQ34976999-B8A41B8A-2E1A-4E9F-922F-C48BA8FFE3ABQ35057734-468D700D-CA57-4D79-B117-895F92E6614FQ35716603-CA26CF61-BECB-4DBF-A823-0EF2D02E0354Q35729544-D8221C88-19F9-4F99-B64E-F9369E9F10B9Q36172314-4546F116-6984-4D66-9A29-8675E8941857Q36319368-E723F5F9-92E6-4ECD-BA57-A266E3CA4C91Q36327523-485FD0BC-3211-4706-9C23-F133228F7C68Q37000515-29F7B8DD-6EAD-40F2-91EF-5BF6A93C7E93Q37233074-502DEA9A-F0AC-4C54-A3F8-7719EAE00A2BQ37254045-9E52FFB8-D16F-4E55-B499-DBF2C53E7285Q37264576-26DE5F23-9D4D-4CCF-BD2B-BB6A8D210103Q37278724-1DBD4AB2-C565-460E-B5DB-2620C15E8546Q37531320-86BD57DE-B308-47CA-8D52-4E7D5D06C6ACQ37965692-7C17674A-4CCB-459F-9B66-8DB43ED1CA43Q38404888-B8742953-044B-4099-A7C2-4A33795CA55DQ38422593-EC9A2ABE-7515-458D-A46E-F51B9A611675
P50
name
Sabine Yerly
@ast
Sabine Yerly
@en
Sabine Yerly
@nl
type
label
Sabine Yerly
@ast
Sabine Yerly
@en
Sabine Yerly
@nl
prefLabel
Sabine Yerly
@ast
Sabine Yerly
@en
Sabine Yerly
@nl